CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: 16832/S015

Trade Name: CYLERT TABLETS

Generic Name: PEMOLINE

Sponsor: ABBOTT LABORATORIES

Approval Date: 12/12/97

Indication(s): TREATMENT OF ATTENTION DEFICIT DISORDER

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION: 16832/S015

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				X
Approvable Letter				X
Final Printed Labeling				X
Medical Review(s)				X
Chemistry Review(s)				X
EA/FONSI				X
Pharmacology Review(s)				X
Statistical Review(s)				X
Microbiology Review(s)				X
Clinical Pharmacology Biopharmaceutics Review(s)				X
Bioequivalence Review(s)				X
Administrative Document(s)/ Correspondence	X			

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: 16832/S015

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 16-832/S-015
NDA 17-703/S-013

DEC 12 1997

Abbott Laboratories
Attention: Matthew A. Biondi
100 Abbott Park Road
D-491, AP6B-1SW
Abbott Park, Illinois 60064-3500

APPEARS THIS WAY
ON ORIGINAL

Dear Mr. Biondi:

We acknowledge your supplemental new drug application dated November 4, 1997, received November 5, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cylert[R] (pemoline) Tablets and Chewable Tablets.

The supplemental application provides for new safety warnings concerning the occurrence of fatal and/or potentially fatal acute liver failure associated with pemoline's usage, as requested in our October 30, 1996, letter.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drugs are safe and effective for use as recommended in the final printed labeling submitted on November 4, 1997. Accordingly, the supplemental applications are approved effective on the date of this letter.

If you have any questions, please contact Anna Marie Weikel, R.Ph., Project Manager, at (301) 594-5536.

Sincerely yours,

/S/ 12/11/97

Paul Leber, M.D.
Director
Division of Neuropharmacological
Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

APPEARS THIS WAY
ON ORIGINAL

cc:
Original NDA 16-832 & 17-703 /S/ 12-11-97
HFD-120/Div. files
HFD-120/Leber /S/ 12/9/97
HFD-120/Laughren/12.9.97/Mosholder/12.8.97
HFD-120/Purvis/12.8.97 /S/ 12/9/97
HFD-120/Weikel
DISTRICT OFFICE /S/ 12/11/97
HF-2/Medwatch (with labeling)
HFD-92/DDM-DIAB (with labeling)
HFD-40/DDMAC (with labeling)
HFD-613/OGD (with labeling)
HFI-20/Press Office (with labeling)

Drafted by: AMW/12.05.97
C:\WPFILES\NDA\CYLERT\N16832S1.AP
final: AMW/12.09.97

APPROVAL (AP)

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 16832/S015

ADMINISTRATIVE DOCUMENTS/CORRESPONDENCE

Division of Neuropharmacological Drug Products

PROJECT MANAGER LABELING REVIEW

NDA#: 16-832/S-015
17-703/S-013

Product Name:
Cylert[R] (pemoline)

Date Review Completed: December 4, 1997

Date of Submissions: November 4, 1997

Provides for:

1. Addition of statements to the 'Indications and Usage' section cautioning against use of Cylert as first line drug therapy for ADHD.

2. Addition of a boxed warning to the 'Warnings' section regarding the occurences of acute hepatic failure with Cylert usage.

3. Changes to the 'Precautions' section regarding the need for increased liver monitoring.

4. Changes to the 'Adverse Reactions' section regarding hepatic dysfunction.

Applicant's Name and Address:

Abbott Pharmaceutical Products Division
100 Abbott Park Road
Abbott Park, IL 60064

Dosage Form and Strength:
Oral Tablets, 18.75, 37.5 & 75 mg
Chewable Tablets 37.5 mg

Material Reviewed:

1. FPL submitted in 16-832/S-015 & 17-703/S-013 dated November 4, 1997, and the February 12, 1997, general correspondence.

2. 16-832/S-013 & 17-703/S-011: Agency approval letter dated April 11, 1996, and the FPL contained in the January 5, 1996, FPL submission (last approved FPL).

3. The October 30, 1996, Agency letter requesting labeling changes.

Background:

This 'Special Supplement - Changes Being Effected' labeling supplement was requested in a October 30, 1996, Agency letter due to concerns about acute hepatic failure in children.

Labeling Review:

Conclusion:

A side-by-side comparison between the most recently approved package insert FPL (03-4633-R17-Rev. December 1995), approved on April 11, 1996, and the FPL (03-4735-R18-Rev. December 1996) provided in this supplement, shows the exact revisions that were requested in the Agency 10/30/96 letter.

Therefore, with the concurrence of the clinical reviewers, a supplement approval letter seems appropriate for these new revisions to the labeling.

/S/

Anna Marie H. Weikel
Project Manager

Concur: /S/ 12/8/97

John S. Purvis
Supervisory CSO

cc:
Orig NDA 16-832 & 17-703
HFD-120
HFD-120/Weikel

C:\WPFILES\NDA\LABELREV\CYLERS15.LR

4 Page(s) Redacted

DRAFT

Labeling

DEPARTMENT OF HEAL[T]H & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

JUN 20 1997

NDAs 19-204, 19-057, 11-971, 18-279, 12-524, 12-775,
20-347, 05-545, 16-832, 17-703
05-378, 10-021, 10-841, 19-080, 17-105,
05-856, 20-680, 20-471, 50-662, 50-611

ANDAs 61-904, 61-905, 62-746, 61-621,
60-359, 62-298, 83-245, 84-093, 83-220



Abbott
Pharmaceutical Products Division
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500

Attention: Richard Poska
Senior Regulatory Affairs Administrator
Abbott Laboratories

Dear Mr. Poska:

Please refer to your letters dated April 17 and May 13, 1997. We also refer to your April 8, 1997, telephone conversation with Dr. Eric Sheinin and your May 13 and 19, 1997, telephone conversations with Dr. Yuan-yuan Chiu, both of this Agency.

In your letters you have provided information to support proposed changes as "Special Supplements - Changes Being Effected" for several of your approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).

It is our opinion that the changes as proposed may be submitted as "Special Supplements - Changes Being Effected".

In addition, the packaging should also be tested according to Consumer Product Safety Commission regulations. We understand that you will specify the package sizes and configurations applicable to each product in each supplement since not all package sizes and configurations will be used for every drug product.

Data from stability studies are not required for the submission of the supplements. However, stability testing should be initiated on the first production batch based on the approved protocol for selection of batches of different strengths and packaging sizes and configurations. The data from the stability studies should be submitted in the annual reports for each NDA and ANDA.

It would be helpful to each review division if you included a copy of this letter with each supplement.

Should you have any questions, please contact:

For NDAs: Susan Lange, M.P.H.
Consumer Safety Officer
Office of New Drug Chemistry
(301) 827-5173

For ANDAs: Mark Anderson, R.PH.
Project Manager
Office of Generic Drugs
(301) 827-5848

Sincerely,

/S/

Eric B. Sheinin, Ph.D.
Director
Office of New Drug Chemistry
Office of Pharmaceutical Sciences
Center for Drug Evaluation
and Research

Sincerely,

/S/

Douglas L. Sporn
Director
Office of Generic Drugs
Office of Pharmaceutical Science
Center for Drug Evaluation
and Research

ABBOTT

Pharmaceutical Products Division

Abbott Laboratories
100 Abbott Park Road
D-491, AP6B-1SW
Abbott Park, Illinois 60064-3500

February 10, 1998

ORIGINAL

NDA SUPPL AMEND
SCP-014
(BC)

CENTER FOR DRUG EVALUATION AND RESEARCH

FEB 11 1998

RECEIVED HFD-120

Donald Klein, Ph.D.
Division of Neuropharmacological Drug Products
HFD-120, Woodmont Office Complex 2
Food and Drug Administration
Center for Drug Evaluation and Research
1451 Rockville Pike
Rockville, MD 20852

Re: NDA 16-832/S-016
~~NDA 17-703/S-014~~
NDA 18-081/S-030

NDA 19-680/S-013

APPEARS THIS WAY ON ORIGINAL

Dear Dr. Klein:

The sponsor, Abbott Laboratories, submits the enclosed information in support of our pending Supplemental New Drug Applications for the above referenced NDA products, submitted as changes-being-effected supplements

Reference is made to your telephone call today in which you requested information on the manufacturing, packaging, and control sites for drug substance and drug product for these NDAs.

Enclosed is the requested information.

Should you have any questions or comments regarding this submission, please contact me at the number listed below

Sincerely,

ABBOTT LABORATORIES

APPEARS THIS WAY ON ORIGINAL

James D. Steck

James D. Steck
Director, PPD Regulatory Affairs
Phone: (847) 937-0335
Fax: (847) 937-8002

SET:kdh
Enclosures

Copy of this Cover Letter to:
Jackie Ware, Pharm. D., Project Manager
Division of Neuropharmacological Drug Products
HFD-120, Woodmont Office Complex 2
Food and Drug Administration
Center for Drug Evaluation and Research
1451 Rockville Pike
Rockville, MD 20852